Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain
- 1 January 1988
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 146 (1) , 113-120
- https://doi.org/10.1016/0014-2999(88)90492-x
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Evidence for Different States of the Dopamine Dl Receptor: Clozapine and Fluperlapine May Preferentially Label an Adenylate Cyclase-Coupled State of the Dl ReceptorJournal of Neurochemistry, 1986
- The Benzazepine, SCH 23390, Inhibits 3H‐NPA Binding in Mouse Brain In VivoActa Pharmacologica et Toxicologica, 1986
- Specific binding of 3H-SCH 23390 to dopamine D1 receptorsLife Sciences, 1986
- Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivoEuropean Journal of Pharmacology, 1986
- A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatumLife Sciences, 1985
- Specific in vitro and in vivo binding of 3H-raclopride a potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brainBiochemical Pharmacology, 1985
- Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugsEuropean Journal of Pharmacology, 1985
- Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatumLife Sciences, 1984
- Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neurolepticsLife Sciences, 1984
- Antipsychotic drug doses and neuroleptic/dopamine receptorsNature, 1976